Trust Co. of Toledo NA OH Makes New Investment in IQVIA Holdings Inc. $IQV

Trust Co. of Toledo NA OH acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 245 shares of the medical research company’s stock, valued at approximately $39,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Inspire Investing LLC lifted its holdings in IQVIA by 1.8% in the 2nd quarter. Inspire Investing LLC now owns 19,434 shares of the medical research company’s stock worth $3,063,000 after buying an additional 347 shares in the last quarter. Aberdeen Group plc lifted its holdings in IQVIA by 4.3% in the 2nd quarter. Aberdeen Group plc now owns 143,803 shares of the medical research company’s stock worth $22,662,000 after buying an additional 5,960 shares in the last quarter. Blue Trust Inc. lifted its holdings in IQVIA by 64.2% in the 2nd quarter. Blue Trust Inc. now owns 491 shares of the medical research company’s stock worth $77,000 after buying an additional 192 shares in the last quarter. IFP Advisors Inc raised its stake in shares of IQVIA by 170.3% in the 2nd quarter. IFP Advisors Inc now owns 1,630 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 1,027 shares in the last quarter. Finally, Callan Family Office LLC raised its stake in shares of IQVIA by 342.3% in the 2nd quarter. Callan Family Office LLC now owns 6,227 shares of the medical research company’s stock valued at $981,000 after purchasing an additional 4,819 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $203.95 on Tuesday. The company’s 50-day moving average price is $189.44 and its 200 day moving average price is $168.30. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The firm has a market cap of $34.67 billion, a price-to-earnings ratio of 29.52, a price-to-earnings-growth ratio of 2.18 and a beta of 1.32. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the business earned $2.64 earnings per share. IQVIA’s revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IQV. Cowen restated a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group upped their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a research note on Thursday. Barclays upped their target price on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Finally, Redburn Partners set a $214.00 target price on shares of IQVIA in a research note on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $234.57.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.